End Kidney Deaths Act
Summary
The End Kidney Deaths Act (HR2687) is an early-stage House bill offering a $50,000 refundable tax credit over five years for non-directed living kidney donors. With 47 cosponsors and only a referral to two committees, the bill is procedurally distant from passage. The structural tailwind for transplant-related clinical lab volumes at Labcorp ($LH) and Quest Diagnostics ($DGX) is real but de minimis relative to their total operations. No market-moving impact at this legislative stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2687 is an early-stage bill with 47 cosponsors, referred to two committees — significant legislative path remains before any market impact
- 2.The $50,000 refundable tax credit is a tax expenditure, not direct spending — no procurement or contracting mechanism exists
- 3.Labcorp and Quest Diagnostics would see de minimis revenue lift from any increase in living donor transplants; impact is below materiality thresholds
- 4.Real market data for $LH and $DGX shows no abnormal price movement linked to this legislation
Market Implications
There is no actionable market signal from HR2687 at this stage. Both (current $262.73) and (current $195.17) are trading within their 52-week ranges with normal volatility. The bill's potential to drive transplant testing volumes is structurally real but financially immaterial — annual revenue impact would be measured in single-digit millions against multi-billion dollar revenue bases. Investors should not trade on this bill. The only scenario that changes this assessment is committee markup with amendments, introduction of a Senate companion bill, or a Congressional Budget Office score showing meaningful projected transplant volume increases.
Full Analysis
The End Kidney Deaths Act (HR2687) was introduced in the House on April 7, 2025 by Rep. Malliotakis (R-NY) and referred to the Ways and Means and Energy and Commerce Committees. The bill provides a $50,000 refundable tax credit ($10,000/year for five years) for individuals who make non-directed living kidney donations. This is an early-stage authorization bill — it does not appropriate any funds, only creates a tax credit mechanism through the tax code.
The money trail is a tax expenditure: the federal government forgoes up to $50,000 per donor over five years. There is no direct contracting or procurement. The incentive is designed to increase the supply of living kidney donors, which would modestly increase the number of kidney transplants performed annually. Currently about 6,000 living donor kidney transplants occur per year in the US; a 10% increase would add ~600 procedures.
Structural winners are Labcorp and Quest Diagnostics, which perform HLA typing, crossmatching, viral screening, and post-transplant monitoring for kidney transplant programs. However, transplant-related testing represents a tiny fraction of each company's revenue. Labcorp's total 2025 revenue is approximately $14 billion; Quest's is about $10 billion. Even a generous estimate of incremental transplant testing revenue ($2-3 million annually) is immaterial to either company's bottom line.
Real market data shows at $262.73 (down 1.53% over 30 days) and at $195.17 (down 0.41% over 30 days). Both stocks are within their 52-week ranges, showing no abnormal price action linked to this bill. The 7-day changes (-0.41% for , -0.56% for ) are consistent with normal trading patterns.
Legislative timeline: The bill has 47 cosponsors from both parties and is in two committees. It requires committee markup, House floor vote, Senate introduction and passage (no companion bill exists yet), and presidential signature. Given that this is the 119th Congress (2025-2027), the earliest possible passage would be late 2026. With no companion bill and the current committee referral status, the bill is unlikely to advance significantly this session.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →